Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daron Ferris

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Proteomics. Clinical Applications|October 17, 2009
Characterization of Molecular Markers Indicative of Cervical Cancer ProgressionHilal Arnouk, Mark A Merkley, Robert H Podolsky, et al.
Tumour Virus Research|May 7, 2022
Human papillomavirus seroprevalence and seroconversion following baseline detection of nine human papillomavirus types in young womenDarron R Brown, Xavier Castellsagué, Daron Ferris, et al.
Journal of Lower Genital Tract Disease|December 27, 2005
Preparing digitized cervigrams for colposcopy research and education: determination of optimal resolution and compression parametersJose Jeronimo, Rodney Long, Leif Neve, et al.
Journal of Women'S Health & Gender-Based Medicine|May 4, 2002
The acceptability of self-collected samples for HPV testing vs. the pap test as alternatives in cervical cancer screeningIlana G Dzuba, Elsa Yunes Díaz, Betania Allen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 4, 2018
A Phase 2, Randomized, Control Trial of Group B Streptococcus (GBS) Type III Capsular Polysaccharide-tetanus Toxoid (GBS III-TT) Vaccine to Prevent Vaginal Colonization With GBS IIISharon L Hillier, Patricia Ferrieri, Morven S Edwards, et al.
Plos One|November 19, 2013
Serum protein profile at remission can accurately assess therapeutic outcomes and survival for serous ovarian cancerJinhua Wang, Ashok Sharma, Sharad A Ghamande, et al.
The Journal of Infectious Diseases|February 6, 2014
Incidence, clearance, and disease progression of genital human papillomavirus infection in heterosexual menEdson Duarte Moreira, Anna R Giuliano, Joel Palefsky, et al.
Pediatrics|August 20, 2014
Long-term study of a quadrivalent human papillomavirus vaccineDaron Ferris, Rudiwilai Samakoses, Stan L Block, et al.
Papillomavirus Research (Amsterdam, Netherlands)|July 14, 2020
Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-upSven-Eric Olsson, Jaime Alberto Restrepo, Julio Cesar Reina, et al.
Human Vaccines|June 30, 2011
Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adultsEdson D Moreira, Joel M Palefsky, Anna R Giuliano, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Proteomics. Clinical Applications|October 17, 2009
Characterization of Molecular Markers Indicative of Cervical Cancer ProgressionHilal Arnouk, Mark A Merkley, Robert H Podolsky, et al.
Tumour Virus Research|May 7, 2022
Human papillomavirus seroprevalence and seroconversion following baseline detection of nine human papillomavirus types in young womenDarron R Brown, Xavier Castellsagué, Daron Ferris, et al.
Journal of Lower Genital Tract Disease|December 27, 2005
Preparing digitized cervigrams for colposcopy research and education: determination of optimal resolution and compression parametersJose Jeronimo, Rodney Long, Leif Neve, et al.
Journal of Women'S Health & Gender-Based Medicine|May 4, 2002
The acceptability of self-collected samples for HPV testing vs. the pap test as alternatives in cervical cancer screeningIlana G Dzuba, Elsa Yunes Díaz, Betania Allen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 4, 2018
A Phase 2, Randomized, Control Trial of Group B Streptococcus (GBS) Type III Capsular Polysaccharide-tetanus Toxoid (GBS III-TT) Vaccine to Prevent Vaginal Colonization With GBS IIISharon L Hillier, Patricia Ferrieri, Morven S Edwards, et al.
Plos One|November 19, 2013
Serum protein profile at remission can accurately assess therapeutic outcomes and survival for serous ovarian cancerJinhua Wang, Ashok Sharma, Sharad A Ghamande, et al.
The Journal of Infectious Diseases|February 6, 2014
Incidence, clearance, and disease progression of genital human papillomavirus infection in heterosexual menEdson Duarte Moreira, Anna R Giuliano, Joel Palefsky, et al.
Pediatrics|August 20, 2014
Long-term study of a quadrivalent human papillomavirus vaccineDaron Ferris, Rudiwilai Samakoses, Stan L Block, et al.
Papillomavirus Research (Amsterdam, Netherlands)|July 14, 2020
Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-upSven-Eric Olsson, Jaime Alberto Restrepo, Julio Cesar Reina, et al.
Human Vaccines|June 30, 2011
Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adultsEdson D Moreira, Joel M Palefsky, Anna R Giuliano, et al.
Pageof 3